The safety of cyclosporine and tacrolimus in pediatric nephrotic syndrome patients: a disproportionate analysis based on the FAERS database

The safety of cyclosporine and tacrolimus in pediatric nephrotic syndrome patients: a disproportionate analysis based on the FAERS database

ObjectiveThis study aimed to systematically evaluate the safety of cyclosporine (CsA) and tacrolimus (TAC) in pediatric nephrotic syndrome (NS) patients using real-world data from the FDA Adverse Event Reporting System (FAERS).MethodsWe analyzed adverse event (AE) reports from the FAERS database bet...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu Liu, Chong Yan, Yaowang Zhao, Sui Deng, Jiancheng Zu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pediatrics
Subjects:	tacrolimus nephrotic syndrome pediatrics FAERS real-world data cyclosporine
Online Access:	https://www.frontiersin.org/articles/10.3389/fped.2024.1487441/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

Cyclosporin, Tacrolimus, Mycophenolic Acid, and Dexamethasone Suppress Peripheral Blood Mononuclear Cell Proliferation and Inhibit Interferon-Gamma, IL-10 and IL-13 Production <em>In Vitro</em>
by: Abdel-Rahman Youssef
Published: (2024-12-01)

Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS
by: Lin Li
Published: (2025-01-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

He effect of cyclosporine in lambs with oral papillomatosis
by: Fahrettin Alkan, et al.

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

A Case of Repeat Kidney Transplant Intolerant to Multiple First-line Immunosuppressive Agents Mycophenolate Mofetil, Azathioprine, and Calcineurin Inhibitors
by: Puneet Arora, et al.
Published: (2024-12-01)

Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
by: Qinyun Xu, et al.
Published: (2025-01-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

Edematous striae distensae in nephrotic syndrome
by: Swarup Kumar Patnaik, et al.
Published: (2016-07-01)

Urinary interleukin 13 level in steroid sensitive and resistant nephrotic syndrome: a cross-sectional single center study
by: Behnam Ermian, et al.
Published: (2025-02-01)

Cross-Linking the TCR Complex Induces Apoptosis in CD4+8+ Thymocytes in the Presence of Cyclosporin A
by: Heather L. Poetschke, et al.
Published: (1996-01-01)

Forced degradation of tacrolimus and the development of a UHPLC method for impurities determination
by: Peterka Tanja Rozman, et al.
Published: (2019-09-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Corticosteroid-sparing topical treatment with cyclosporin for juvenile keratoconjunctivitis
by: Amarilla Barcsay-Veres, et al.
Published: (2025-02-01)

Nephrotic and Non-Nephrotic Focal Segmental Glomerulosclerosis: Clinical Characteristics, Etiology, and Columbia Classification
by: Gabriel Figueiredo, et al.
Published: (2025-01-01)

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
by: Qian Qiao, et al.
Published: (2025-01-01)

Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients
by: Alan D. Kaye, et al.
Published: (2024-12-01)

Tacrolimus trough level and oxidative stress in Tunisian kidney transplanted patients
by: Mariam Ammar, et al.
Published: (2024-12-01)

Case Report: Nephrotic syndrome as the primary manifestation of Alport syndrome in a Chinese pediatric patient
by: Yue Song, et al.
Published: (2025-01-01)

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
by: Zhishen Ruan, et al.
Published: (2025-01-01)

Case report: Novel ACTN4 variant of uncertain significance in a pediatric case of steroid-resistant nephrotic syndrome requesting kidney transplantation
by: Ignacio Alarcón, et al.
Published: (2025-01-01)

Cyclosporine A and autologous serum efficacy for treatment of vernal keratoconjunctivitis
by: Ahmed Esmail, et al.
Published: (2024-05-01)

Changes in Serum Immunoglobulin Levels Play as Predictors of Treatment Response and Prognosis in Pediatric Idiopathic Nephrotic Syndrome During the Remission Phase
by: Amin sadat Sharif, et al.
Published: (2025-01-01)

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults
by: Hao Li, et al.
Published: (2025-01-01)

Evaluation of efficacy and safety of generic tacrolimus (Suprotac®) compared to reference tacrolimus (Prograf<sup>®</sup>) in kidney transplantation: a phase IV study
by: Behzad Einollahi, et al.
Published: (2025-01-01)

Clinical efficacy of 0.1% cyclosporine A in dry eye patients with inadequate responses to 0.05% cyclosporine A: a switching, prospective, open-label, multicenter study
by: Sook Hyun Yoon, et al.
Published: (2025-01-01)

Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
by: Wenwen Zhang, et al.
Published: (2025-01-01)

A Prospective Study to Assess the Best Optimal Dose of Tacrolimus before Renal Transplantation and Its Impact on Graft Survival and Patient Outcome in Renal Transplant Recipients
by: Niranjan Gogoi, et al.
Published: (2024-12-01)

Increased behavioural problems associated with corticosteroid use in children with nephrotic syndrome: a Southeast Asian perspective
by: Mohamad Nizam Mahmud, et al.
Published: (2023-09-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Tacrolimus and mycophenolate mofetil in corticosteroid-resistant hepatitis secondary to tislelizumab: a case report
by: Chang Jiang, et al.
Published: (2025-02-01)

Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in nephrotic syndrome patients: a retrospective study
by: Ahmed El-Bardissy, et al.
Published: (2025-01-01)

Effect of Hematopoietic Stem Cell Transplantation Regimen on Tacrolimus Pharmacokinetics
by: Haruno Oku, BS, et al.
Published: (2025-01-01)

Kinetic-pharmacodynamic model to predict post-rituximab B-cell repletion as a predictor of relapse in pediatric idiopathic nephrotic syndrome
by: Ziwei Li, et al.
Published: (2025-01-01)

Efficacy of cyclosporine eyedrop 0.1% in the treatment of dry eye in primary sjogren's syndrome: A prospective Indian study
by: Swapnali Sabhapandit, et al.
Published: (2023-01-01)

RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease
by: Zhaochen Guo, et al.
Published: (2025-02-01)

Overt Hypothyroidism and Severe Growth Retardation in a Preschool Girl with Poorly Controlled Nephrotic Syndrome: Case Report and Literature Review
by: Joana Mikulevič, et al.
Published: (2023-10-01)

Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
by: Laura M. Periman, et al.
Published: (2025-01-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)